【For English】MCI Test

Identify Early Cognitive Decline Before Dementia Develops

Alzheimer’s disease progresses very slowly, often taking decades before symptoms appear. It is now widely recognized that early intervention during the preclinical stage known as Mild Cognitive Impairment (MCI) can help delay or even prevent the onset of dementia. At Kita-Aoyama D.CLINIC, we offer a blood-based MCI screening test that helps identify individuals at risk of developing dementia before clinical symptoms appear.

A key pathological factor in Alzheimer’s disease is the accumulation of amyloid-β peptides in the brain. These peptides are normally cleared from the brain into the blood via cerebrospinal fluid. When amyloid-β builds up, it damages nerve cells and impairs synapses responsible for memory and cognitive function.
The MCI test measures the blood concentration of three specific proteins—APOA1, TTR, and C3—which are involved in either clearing amyloid-β from the brain or protecting synapses from its harmful effects. By analyzing the levels of these proteins, we use statistical modeling to estimate the degree of potential cognitive decline.
This non-invasive blood test allows for early risk assessment and opens the door to preventive strategies before symptoms progress.